Share

August 2021; 11 (4) Research

The Changing Face of Osmotic Demyelination Syndrome

A Retrospective, Observational Cohort Study

Whitney Fitts, Andre C. Vogel, Farrah J. Mateen
First published August 26, 2020, DOI: https://doi.org/10.1212/CPJ.0000000000000932
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
364

Share

Article Information

vol. 11 no. 4 304-310
DOI: 
https://doi.org/10.1212/CPJ.0000000000000932
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received February 13, 2020
  • Accepted May 7, 2020
  • First Published August 26, 2020.

Article Versions

Copyright & Usage: 
© 2021 American Academy of Neurology

Author Disclosures

    1. Whitney Fitts, MD,
    2. Andre C. Vogel, BA and
    3. Farrah J. Mateen, MD, PhD
  1. Whitney Fitts, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Andre C. Vogel, BA and
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Farrah J. Mateen, MD, PhD
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. I have received consulting fees from Oxford Pharmagenesis Ltd., unrelated to this work

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. I have received investigator initiated grant from Biogen, unrelated to this work and after the paper has completed the review process.

    Research Support, Government Entities:

    1. Research funding from the National Institutes of Health as principal investigator, outside of the current work.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Research funding in the form of investigator-initiated grants from the National MS Society and Fondation Pierre Fabre, unrelated to this manuscript.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. Children's Hospital of Philadelphia (WF), PA; Department of Neurology (WF, ACV, FJM), Massachusetts General Hospital, Boston; Harvard Medical School (WF, FJM), Boston, MA.
  1. Correspondence
    Dr. Mateen fmateen{at}partners.org

Article usage

Article usage: August 2020 to October 2023

AbstractFullPdfSource
Aug 202010307Highwire
Sep 2020254017Highwire
Oct 2020182035Highwire
Nov 2020131037Highwire
Dec 202097023Highwire
Jan 202174015Highwire
Feb 202189023Highwire
Mar 2021100023Highwire
Apr 20216909Highwire
May 20217001Highwire
Jun 20215503Highwire
Jul 20216003Highwire
Aug 20216236053Highwire
Sep 20213473219Highwire
Oct 20212321416Highwire
Nov 2021232108Highwire
Dec 2021107108Highwire
Jan 202212189Highwire
Feb 20225656Highwire
Mar 20227132Highwire
Apr 20226813Highwire
May 20226665Highwire
Jun 202271118Highwire
Jul 20228412Highwire
Aug 20228623Highwire
Sep 202216422Highwire
Oct 20229064Highwire
Nov 202217165Highwire
Dec 20229910Highwire
Jan 20238320Highwire
Feb 20235221Highwire
Mar 202310310Highwire
Apr 202313831Highwire
May 20238632Highwire
Jun 202310612Highwire
Jul 202315222Highwire
Aug 202318513Highwire
Sep 202310230Highwire
Oct 20235634Highwire

The Nerve!: Rapid online correspondence

Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles